Comparative analysis of prostatic acid phosphatase and prostate-specific antigen mRNA levels in hyperplastic prostate stimulated with steroid hormones and growth factors.

• Authors: Joanna Dulińska , Piotr Laidler , Maria Łabędź
• Languages of publication: EN

Abstracts

EN

Prostatic acid phosphatase (PAP) and prostate-specific antigen (PSA) are the markers of human prostatic gland. However, it is still not completely understood if and how, steroid hormones and growth factors affect their expression and metabolism in the respect to the major pathologies of the gland. Appropriate studies were carried out on histopathologically diagnosed benign prostatic hyperplasia - BPH (n = 42) using tissue slices and cells derived from them. They were incubated with steroid hormones: 5-α-dihydrotestosterone (DHT), estradiol (E) and growth factors: epidermal growth factor (EGF), basic fibroblastic growth factor (bFGF) under culture conditions for up to 24 hours. 32P-labelled specific oligonucleotide probes were used to analyze total RNA isolated from each sample for the presence of PAP and PSA mRNAs. DHT, E, bFGF, EGF or both DHT + bFGF and DHT + EGF increased PAP and PSA mRNA levels in a time- and dose-dependent manner. The highest and statistically significant increase (P <0.001) for PAP mRNA was observed when DHT + bFGF were present in the medium while for PSA mRNA if DHT + EGF were added to the medium. Slow but constant decrease of PAP and PSA mRNA levels was observed in the absence of each of these factors in the incubation medium. The results suggest that early expression of PSA and PAP genes and/or their mRNA stability strongly depend on DHT while differ in their response to EGF and bFGF.

Keywords

EN

hyperplastic prostate; prostate-specific antigen; androgens; growth factors; prostatic acid phosphatase

• Publisher: Polish Biochemical Society
• Journal: Acta Biochimica Polonica
• Year: 2002
• Volume: 49
• Issue: 2
• Pages: 357-368

Dates

published

2002

received

2001-11-16

revised

2002-04-22

accepted

2002-06-10

Contributors

author

Joanna Dulińska

• Institute of Medical Biochemistry, Medical College, Jagiellonian University, Kraków, Poland

author

Piotr Laidler

• Institute of Medical Biochemistry, Medical College, Jagiellonian University, Kraków, Poland

author

Maria Łabędź

• Institute of Medical Biochemistry, Medical College, Jagiellonian University, Kraków, Poland

References

• Barka T, Andersson PJ. (1962) Histochemical methods for acid phosphatase using pararosanilin as coupler. J Histochem Cytochem.; 10: 741-53.
• Cooper AC, Foti A. (1974) A radioimmunoassay for prostatic acid phosphatase. Investig Urol.; 12: 98-102.
• Daniels WW. (1999) Biostatistics: a fundation for analysis in the health science, New York, Wiley J and Sons.
• Diamandis EP, Yu H. (1995) New biological functions of prostate-specific antigen? J Clin Endocrinol Metab.; 80: 1515-7.
• Dulińska J, Laidler P, Ostrowski WS, Mrozicki S, Gałka M. (1997) The effect of dihydrotestosterone on transcription of prostatic acid phosphatase mRNA in human hyperplastic gland. Acta Biochim Polon.; 44: 751-8.
• Farnsworth WE. (1996) Roles of estrogen and SHBG in prostate physiology. Prostate.; 28: 17-23.
• Frydenberg M, Foo TM, Jones AS, Grace J, Hensley WJ, Rogers J, Pearson BS, Raghavan D. (1991) Benign prostatic hyperplasia - video image analysis and its relationship to androgen and epidermal growth factor receptor expression. J Urol.; 146: 872-6.
• Garcia-Arenas R, Lin FF, Lin D, Jin LP, Shih CC-Y, Chang C, Lin MF. (1995) The expression of prostate acid phosphatase is transcriptionally regulated in human prostate carcinoma cells. Mol Cell Endocrinol.; 111: 29-37.
• Geller J. (1990) Effect of finasteride, a 5α-reductase inhibitor on prostate tissue androgens and prostate-specific antigen. J Clin Endocrinol Metab.; 71: 1552-5.
• Guenette RS, Tenniswood M. (1994) The role of growth factors in the suppression of active cell death in the prostate: an hypothesis. Biochem Cell Biol.; 72: 553-9.
• Henttu P, Vihko P. (1992) Steroids inversely affect the biosynthesis and secretion of human prostatic acid phosphatase and prostate-specific antigen in the LNCaP cell line. J Steroid Biochem Mol Biol.; 41: 349-60.
• Henttu P, Liao S, Vihko P. (1992) Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA), but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line. Endocrinology; 130: 766-72.
• Heston WD. (1996) Significance of prostate-specific membrane antigen (PSMA) aneurocarboxypeptidase and membrane folate hydrolase. Urologe A.; 35: 400-7.
• Isaacs JT. (1994) Role of androgens in prostatic cancer. Vitam Horm.; 49: 433-502.
• Janssen T, Kiss R, Dedecker R, Petein M, Pasteels JL, Schulman C. (1995) Influence of dihydrotestosterone, epidermal growth factor, and basic fibroblast growth factor on the cell kinetics of the PC3, DU 145, and LNCaP prostatic cancer cell lines: relationships with DNA ploidy level. Prostate.; 27: 277-86.
• Kim IY, Kim JH, Zelner DJ, Ahn HJ, Sensibar JA, Lee Ch. (1996) Transforming growth factor-β1 is a mediator of anrdogen-regulated growth arrest in an androgen-responsive prostatic cancer cell line, LNCaP. Endocrinology.; 137: 991-9.
• Krieg M, Bartsch W, Herzer S, Becker H, Voigt KD. (1977) Quantification of androgen binding, androgen tissue levels, and sex hormone-binding globulin in prostate, muscle and plasma of patients with benign prostatic hypertrophy Acta Endocrinol (Copenh).; 86: 200-15.
• Lin MF, Garcia-Arenas R, Chao Ych, Lai MMC, Patel PC, Xia XZ. (1993) Regulation of prostatic acid phosphatase expression and secretion by androgen in LNCaP prostate carcinoma. Arch Biochem Biophys.; 300: 384-90.
• Lin MF, Meng TC, Rao PS, Chang C, Schonthal AH, Lin FF. (1998) Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines. J Biol Chem.; 273: 5939-47.
• McConnell JD, Wilson JD, George FW, Geller J, Papppas F, Stoner E. (1992) Finasteride, an inhibitor of 5α-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab.; 74: 505-8.
• Meng TC, Lin MF. (1998) Tyrosine phosphorylation of c-ErbB-2 is regulated by the cellular form of prostatic acid phosphatase in human prostate cancer cells J Biol Chem.; 273: 22096-104.
• Meng TC, Lee MS, Lin MF. (2000) Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth oh human prostate cancer cells. Oncogene.; 19: 2664-77.
• Murtha P, Tindall DC, Young CY. (1993) Androgen induction of a human prostate-specific kallikrein, hKLK2: characterization of an androgen response element in the 5' promoter region of the gene. Biochemistry.; 32: 6459-6464.
• Mydlo J, Michaeli, J, Heston, W, Fair W. (1988) Expression of basic fibroblastic growth factor mRNA in benign prostatic hyperplasia and prostatic carcinoma. Prostate; 13: 241-7.
• Nevalainen MT, Harkonen PL, Valve EM, Ping W, Nurmi W, Martikainen PM. (1993) Hormone regulation of human prostate in organ culture. Cancer Res.; 53: 5199-207.
• Ostrowski W, Tsugita A. (1961) Purification of acid phosphomonoesterase from human prostate gland. Arch Biochem.; 94: 68-73.
• Pamies RJ, Crawford DR. (1996) Tumor markers. An update. Med Clin North Am.; 80: 185-99.
• Peterziel H, Mink S, Schonert A, Becker M, Klocker H, Cato ACB. (1999) Rapid signaling by androgen receptor in prostate cancer cells. Oncogene.; 18: 6322-9.
• Pilarsky CP, Schmidt U, Eissrich C, Stade J, Froschermaier SE, Haase M, Faller G, Kirchner TW, Wirth MP. (1998) Expression of the extracellular matrix signalling molecule Cyr61 is downregulated in prostate cancer. Prostate.; 36: 85-91.
• Robert M, Gibbs B.F, Jacobsen T, Gangon C. (1995) Characterization of prostate specific antigen proteolitic activity on its major physiological substrate, the sperm motility inhibitor precursor/semenogelin I. Biochemistry.; 36: 3811-6.
• Rosner W, Hryb DJ, Khan MS, Nakhla AM, Romas NA. (1999) Sex hormone-binding globulin mediates steroid hormone signal transduction at the plasma membrane. J Steroid Biochem Molec Biol.; 69: 481-5.
• Saez C, Gonzalez-Baena AC, Japon MA, Giraldez J, Segura DI, Rodriguez-Vallejo JM, Gonzalez-Esteban J, Miranda G, Torrubia F. (1999) Expression of basic fibroblast growth factor and its receptors FGFR1 and FGFR2 in human benign prostatic hyperplasia treated with finasteride. Prostate.; 40: 83-8.
• Sherwood ER, Fong CJ, Lee C, Kozłowski JM. (1992) Basic fibroblast growth factor: a potential mediator of stromal growth in the human prostate. Endocrinology.; 130: 2955-63.
• Shuurmans ALG, Bolt J, Veldscholte J, Mulder E. (1991) Regulation of growth factors and steroid hormones. J Steroid Biochem Mol Biol.; 40: 193-7.
• Solin T, Kontturi M, Pohlmann R, Vihko P. (1990) Gene expression and prostate specificity of human prostatic acid phosphatase (PAP): evolution by RNA blot analyses Biochim Biophys Acta.; 1048: 72-7.
• Tenniswood MP, Montpetit NL, Leger JG, Wong P, Pineault JM, Rouleau M. (1990) Epithelial-stromal interactions and cell death in the prostate. In The prostate as an endocrine gland. Fornsworh WE, Ablin RJ. eds, pp 187-207. CRC Press, Boca Raton, Fla.
• Van Helden PD, Wiid IJF, Hoal-van Helden EG, Bey E, Cohen, R. (1994) Detection by DNA fingerprinting of somatic changes during the establishment of a new prostate cell line Br J Cancer.; 70: 195-8.
• Vihko P, Virkkunen P, Henttu P, Roiko K, Solin T, Huhtala ML. (1988) Molecular cloning and sequence analysis of cDNA encoding human prostatic acid phosphatase. FEBS Lett.; 236: 275-81.
• Watt KWT, Lee PJ, M'Timkulu T, Chan WP, Loor R. (1986) Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci U S A.; 83: 3166-70.
• Zelivianski S, Larson C, Seberger J, Taylor R, Lin MF. (2000) Expression of human prostatic acid phosphatase gene is regulated by upstream negative and positive elements Biochim Biophys Acta.; 1491: 123-32.